Judge Says Marketing Exclusivity Begins With FDA Sign-Off on Drug

A federal judge agreed with the FDA’s interpretation that marketing exclusivity begins with NDA approval — and not the date of controlled substance scheduling — rejecting Eisai’s bid to restore exclusivity for two of its drugs.




Click below link : 

http://www.fdanews.com/DID1007152?hittrk=DID15O1

• Tweet
• Share
• Share
• Share
• Share